公开(公告)号：EP2365823B1

公开(公告)日：2016-11-30

申请号：EP09764302.7

申请日：2009-10-29

Applicant: Yeda Research And Development Company Ltd.

Inventor： REISNER, Yair ,  OPHIR, Eran ,  EIDELSTEIN, Yaki ,  BACHAR-LUSTIG, Esther

IPC: C12N5/0783 ,  A61K35/12 ,  A61K39/00

CPC classification number: C12N5/0636 ,  A61K39/001 ,  A61K2035/122 ,  C12N2501/23

Abstract: An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.

公开(公告)号：EP0912611B1

公开(公告)日：2003-12-10

申请号：EP97924227.8

申请日：1997-06-10

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. ,  XTL Biopharmaceuticals Limited

Inventor： REISNER, Yair ,  DAGAN, Shlomo

IPC: C07K16/08 ,  A61K39/29 ,  A61K39/42 ,  C12N5/28 ,  G01N33/569 ,  G01N33/577

CPC classification number: A01K67/0271 ,  A61K38/00 ,  A61K39/00 ,  C07K16/082

Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

公开(公告)号：EP1244803B1

公开(公告)日：2006-02-22

申请号：EP00983473.0

申请日：2000-12-28

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

Inventor： REISNER, Yair ,  MARTELLI, Massimo

IPC: C12N15/85 ,  A61K35/00 ,  A61K38/00

CPC classification number: C12N5/0636 ,  A61K35/28 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N2501/23 ,  Y02A50/396 ,  A61K2300/00

Abstract: A method of transplanting a transplant derived from a donor into a recipient is disclosed. The method comprises the steps of (a) transplanting the transplant into the recipient; and (b) administering to the recipient a dose including non-alloreactive anti-third party cytotoxic T-lymphocytes (CTLs), wherein the non-alloreactive anti-third party CTLs are generated by directing T-lymphocytes of the donor against a third party antigen or antigens, the dose is substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, thereby preventing or ameliorating both graft rejection by the recipient and graft versus host disease.

公开(公告)号：EP2365823A1

公开(公告)日：2011-09-21

申请号：EP09764302.7

申请日：2009-10-29

Applicant: Yeda Research And Development Company Ltd.

Inventor： REISNER, Yair ,  OPHIR, Eran ,  EIDELSTEIN, Yaki ,  BACHAR-LUSTIG, Esther

IPC: A61K39/00

CPC classification number: C12N5/0636 ,  A61K39/001 ,  A61K2035/122 ,  C12N2501/23

Abstract: An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.

Abstract translation: 细胞包含非诱导GVHD具有中枢记忆性T淋巴细胞的抗第三方细胞的分离的人口提供（TCM）的表型。 细胞是诱导耐受性细胞能够归巢到移植后的淋巴结肿大。 因此，提供产生相同，使用的相同和治疗方法的方法。

公开(公告)号：EP0699235B1

公开(公告)日：2007-05-09

申请号：EP94917988.1

申请日：1994-05-13

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

Inventor： REISNER, Yair

IPC: C12N15/00

CPC classification number: A61K35/28 ,  A01K67/0271 ,  A61K35/38 ,  A61K35/407 ,  C07K16/109

Abstract: A non-human chimeric animal useful as a model for human HV infection, comprising a mammal M5 having xenogeneic cells; mammal M5 being derived from a mammal M1 treated to substantially destroy its hematopoietic cells and then transplanted with hematopoietic cells derived from one or more mammals M2 and transplanted with liver tissue from a mammal M3, the one or more mammals M2 and mammal M3 being from the same or from a different species; the transplanted hematopoietic cells from the one or more mammals M2 being either one or both of a hematopoietic cell preparation from a T cell deficient mammal or of a T cell depleted mammalian stem cell or bone marrow preparation; the transplanted liver tissue from mammal M3 being either a human liver tissue preparation or a liver tissue preparation from a non-human mammal capable of being infected by HV; the liver tissue preparation in the M5 mammal being infected by HV.

公开(公告)号：EP0912611B9

公开(公告)日：2004-12-01

申请号：EP97924227.8

申请日：1997-06-10

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. ,  XTL Biopharmaceuticals Limited

Inventor： REISNER, Yair ,  DAGAN, Shlomo

IPC: C07K16/08 ,  A61K39/29 ,  A61K39/42 ,  C12N5/28 ,  G01N33/569 ,  G01N33/577

CPC classification number: A01K67/0271 ,  A61K38/00 ,  A61K39/00 ,  C07K16/082

Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

公开(公告)号：EP0912611A1

公开(公告)日：1999-05-06

申请号：EP97924227.0

申请日：1997-06-10

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. ,  XTL Biopharmaceuticals Limited

Inventor： REISNER, Yair ,  DAGAN, Shlomo

IPC: C12N15 ,  A01K67 ,  A61K38 ,  A61K39 ,  C07K16 ,  C12N5 ,  C12P21 ,  G01N33 ,  C12R1

CPC classification number: A01K67/0271 ,  A61K38/00 ,  A61K39/00 ,  C07K16/082

Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

公开(公告)号：EP0699235A1

公开(公告)日：1996-03-06

申请号：EP94917988.0

申请日：1994-05-13

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

Inventor： REISNER, Yair

IPC: A01K67 ,  A61K35 ,  A61K39 ,  C07K16 ,  C12N5 ,  G01N33

CPC classification number: A61K35/28 ,  A01K67/0271 ,  A61K35/38 ,  A61K35/407 ,  C07K16/109

Abstract: A non-human chimeric animal useful as a model for human HV infection, comprising a mammal M5 having xenogeneic cells; mammal M5 being derived from a mammal M1 treated to substantially destroy its hematopoietic cells and then transplanted with hematopoietic cells derived from one or more mammals M2 and transplanted with liver tissue from a mammal M3, the one or more mammals M2 and mammal M3 being from the same or from a different species; the transplanted hematopoietic cells from the one or more mammals M2 being either one or both of a hematopoietic cell preparation from a T cell deficient mammal or of a T cell depleted mammalian stem cell or bone marrow preparation; the transplanted liver tissue from mammal M3 being either a human liver tissue preparation or a liver tissue preparation from a non-human mammal capable of being infected by HV; the liver tissue preparation in the M5 mammal being infected by HV.